NeuroCIM Research Digest

Drug development targets cellular weaknesses via pre-clinical testing then human trials to confirm efficacy. Recent examples include phase 1 AAV gene...

What can Mendelian randomization tell us about GLP-1 receptor activation and psychiatric risk?

• Stronger benefits than weight loss alone:...

• Core insight: NEC in preterm infants triggers neurodevelopmental impairment through gut-derived inflammation, exceeding prematurity risks alone
  -...

At RAPS Convergence 2026, FDA and EMA leaders stressed that representative enrollment now centers on generating reliable evidence for intended...

Emerging evidence frames Alzheimer’s as a systemic immune and metabolic condition rather than a purely neuronal disease.

• Peripheral immune...

FDA's new framework aims to accelerate psychedelic therapies while upholding evidence standards amid the mental health crisis.

• Trial design...

Pairing seed-amplification assays for misfolded proteins with automated speech, facial, and cognitive analytics creates richer datasets for tracking...

Novo Nordisk’s new partnership with Anthropic will test Claude on R&D workflows chosen for maximum expected impact.

• Scientific reasoning in early...

• Patients move from chaotic EDs to dedicated units with recliners and quick psychiatric assessment, often within an hour.
• Short stays (23-72 hours)...

Elevated suicide risk in personality disorders arises from distinct psychosocial pathways that generic strategies overlook.

• Core drivers: Childhood...

This CME activity targets neurologists and memory specialists integrating amyloid-targeting therapies into routine Alzheimer's care.

• Identify...

Prime editing improves safety by using a modified Cas9 that nicks only one DNA strand rather than creating double-stranded breaks, minimizing...

The F-18 AV-1/ZK ligand enables practical PET imaging of beta-amyloid plaques in Alzheimer's patients, revealing neocortical binding patterns...

Lobe's Phase 1a data show L-130, a patented psilocin salt, delivers predictable oral pharmacokinetics with no hallucinogenic effects at low doses,...

Three studies converge on a shared insight: amyloid and tau burden alone fail to predict clinical trajectories.

• Cognitive resilience emerges as a...

The FDA's Expedited IND Pilot pairs drug sponsors with qualified research institutions for rolling pre-IND reviews, targeting a reduction in...

In 3-month-old 5xFAD mice, rule-reversal learning collapses while spatial memory remains intact. The deficit traces to medial prefrontal...

Longevity Vaccines from Insilico use generative AI and circular mRNA in targeted LNPs to transiently equip T cells for clearing senescent lymphocytes,...

Neurons use m6A as a chemical "delivery tag" on RNA, directing specific transcripts to axons via YTHDF2 recognition and transport with FMRP and...

Reaching the 100th enrollment in the Phase 2/3 ALSTARS trial of COYA 302 signals steady progress in evaluating this low-dose IL-2 and CTLA-4 Ig...